Coreline Soft received FDA 510(k) clearance on October 16 for AVIEW Aorta Metrics, software that segments the aorta from chest CT scans and measures diameter zone by zone. It is the Korean company’s 13th US clearance.
The tool automatically classifies aortic regions, measures each one, and produces straightened curved planar reformations, cross-sectional views and 3D renderings for review.
The strategic point is what the software does not need: a dedicated scan. It reads CTs ordered for lungs, heart or anything else, an approach the industry calls opportunistic screening.
One scan, several diseases
Coreline has built AVIEW as a multi-disease platform on a single chest CT. AVIEW LCS and AVIEW Lung Nodule CAD handle nodule detection for cancer screening. AVIEW CAC scores coronary calcium from non-contrast scans. Aorta Metrics now extends that portfolio into cardiovascular anatomy.
US radiology has been drifting this way for two years, as payers and health systems look for extra clinical value from imaging already in the archive rather than new scanner hours.
Getting out of the reading room
Coreline is also moving past one-off hospital installs. It is building PACS-integrated, zero-click automation with INFINITT North America, exploring a lung nodule pathway with Optellum that runs from detection through follow-up, and has worked with Oatmeal Health on screening access.
The company has not disclosed pricing, deployment count in the US or a launch date for the aortic module.
